Clinicopathologic and molecular disease prognostication for papillary thyroid cancer

Expert Review of Anticancer Therapy

Volumn 9, Issue 9, 2009, Pages 1261-1275

  Miccoli, Paolo ^a   Miccoli, Mario ^a   Antonelli, Alessandro ^a   Minuto, Michele N ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Papillary thyroid cancer; Postoperative therapy; Prognostic factors; Surgery

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AXITINIB; B RAF KINASE; LEVOTHYROXINE; MOTESANIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN RET; RADIOACTIVE IODINE; RAS PROTEIN; ROSIGLITAZONE; SORAFENIB; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR PAX8; VANDETANIB;

CANCER INVASION; CANCER MORTALITY; CERVICAL LYMPH NODE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INCIDENCE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; METASTASIS; NONHUMAN; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PROGNOSIS; PROTO ONCOGENE; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SURVIVAL TIME; THYROID CANCER; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TUMOR VOLUME;

ANIMALS; CARCINOMA, PAPILLARY; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 71049183144     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.92     Document Type: Review

References (172)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Center database report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 83, 2638-2648 (1998).
2. Davies L, Welch GH. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295, 2164-2167 (2006). •• Why is thyroid cancer increasingly diagnosed? A very interesting epidemiologic study.
3. Colonna M, Grosclaude P, Remontet L et al. Incidence of thyroid cancer in adults recorded by French cancer registries (1978-1997). Eur. J. Cancer 38(13), 1762-1768 (2002).
4. Heidenreich WF, Kenigsberg J, Jacob P et al. Time trends of thyroid cancer incidence in Belarus after the Chernobyl accident. Radiat. Res. 151, 617-625 (1999). (Pubitemid 29381612)
5. Huszno B, Szybinski Z, Przybylik-Mazurek E et al. Influence of iodine deficiency and iodine prophylaxis on thyroid cancer histotypes and incidence in endemic goiter area. J. Endocrinol. Invest. 26(2 Suppl.), 71-76 (2003).
6. Verkooijen HM, Fioretta G, Pache JC et al. Diagnostic changes as a reason for the increase in papillary thyroid cancer incidence in Geneva, Switzerland. Cancer Causes Control 14, 13-17 (2003). (Pubitemid 36403264)
7. Leenhardt L, Bernier MO, Boin-Pineau MH et al. Advances in diagnostic practices affect thyroid cancer incidence in France. Eur. J. Endocrinol. 150, 133-139 (2004).
8. Surveillance Epidemiology and End-Results (SEER) Program (www.seer. cancer.gov). SEER*Stat Database: Incidence-SEER 9 Regs. Public use, november 2003 sub (1973-2001), National Cancer Institute, DCCPS, surveillance research program, cancer statistics branch, released April 2004, based on the november 2003 submission. National Cancer Institute, Bethesda, MD, USA (2004)
9. Ries LAG, Harkins D, Krapcho D et al. SEER cancer statistics review, 1997-2003 based on november 2005 SEER data submission, posted to the SEER website, 2006: SEER Surveillance Epidemiology And End Results Cancer Statistics Fact Sheets. National Cancer Institute, Bethesda, MD, USA 6-13 (2006).
10. Pinn VW. Sex and gender factors in medical studies: implications for health and clinical practice. JAMA 289, 397-400 (2003).
11. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A national cancer database report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 83, 2638-2648 (1998).
12. Clayman GL, Shellenberger TD, Ginsberg LE et al. Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma. Head Neck 31(9), 1152-1163 (2009).
13. Cooper DS, Doherty GM, Haugen BR et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16, 109-142 (2006).
14. Sherman SI, Angelos P, Ball DW et al. Thyroid carcinoma. J. Natl Compr. Canc. Netw. 3, 404-457 (2005).
15. Mazzaferri EL. An overview of the management of thyroid cancer. In: Practical Management of Thyroid Cancer: a Multidisciplinary Approach. Mazzaferri EL, Harmer C, Mallick UK, Kendall-Taylor P (Eds). Springer-Verlag, London, UK 1-28 (2006).
16. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 97, 418-428 (1994).
17. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 71, 414-424 (1990). (Pubitemid 20261828)
18. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J. Clin. Endocrinol. Metab. 86, 1447-1463 (2001).
19. Sherman SI, Brierley JD, Sperling M et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 83, 1012-1021 (1998).
20. Tanaka K, Sonoo H, Hirono M et al. Retrospective analysis of predictive factors for recurrence after curatively resected papillary thyroid carcinoma. Surg. Today 35, 714-719 (2005). (Pubitemid 41191398)
21. Hung W, Sarlis NJ. Current controversies in the management of pediatric patients with well-differentiated non-medullary thyroid cancer: a review. Thyroid 12, 683-702 (2002). (Pubitemid 34913241)
22. Miccoli P, Minuto MN, Ugolini C et al. Papillary thyroid cancer: pathological parameters as prognostic factors in different classes of age. Otolaryngol. Head Neck Surg. 138(2), 200-203 (2008). (Pubitemid 351172490)
23. Cady B. Staging in thyroid carcinoma. Cancer 83, 844-847 (1998).
24. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J. Clin. Endocrinol. Metab. 86(4), 1447-1463 (2001).
25. Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer 103(11), 2269-2273 (2005). •• Risk stratification for neck lymph node and distant metastases according to the size of the primary tumor.
26. Sywak M, Pasieka J, Ogilvie T. A review of thyroid cancer with intermediate differentiation. J. Surg. Oncol. 86, 44-54 (2004). (Pubitemid 38490100)
27. Machens A, Holzhausen HJ, Lautenschläger C, Dralle H. The tall-cell variant of papillary thyroid carcinoma: a multivariate analysis of clinical risk factors. Langenbecks Arch. Surg. 389(4), 278-282 (2004). (Pubitemid 39128540)
28. Ghossein RA, Leboeuf R, Patel KN et al. Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. Thyroid 17(7), 655-661 (2007). (Pubitemid 47311555)
29. Nikiforov YE, Erickson LA, Nikiforova MN, Caudill CM, Lloyd RV. Solid variant of papillary thyroid carcinoma: incidence, clinical-pathologic characteristics, molecular analysis, and biologic behavior. Am. J. Surg. Pathol. 25(12), 1478-1484 (2001).
30. Jayaram G. Cytology of columnar-cell variant of papillary thyroid carcinoma. Diagn. Cytopathol. 22(4), 227-229 (2000). (Pubitemid 30185817)
31. Shimizu M, Hirokawa M, Manabe T. Tall cell variant of papillary thyroid carcinoma with foci of columnar cell component. Virchows Arch. 434(2), 173-175 (1999). (Pubitemid 29184996)
32. Fujimoto Y, Obara T, Ito Y et al. Diffuse sclerosing variant of papillary carcinoma of the thyroid. Clinical importance, surgical treatment, and follow-up study. Cancer 66, 2306-2312 (1990).
33. Machens A, Holzhausen HJ, Lautenschläger C, Thanh PN, Dralle H. Enhancement of lymph node metastasis and distant metastasis of thyroid carcinoma. Cancer 98(4), 712-719 (2003).
34. Miccoli P, Minuto MN, Ugolini C et al. Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer. Endocr. Relat. Cancer 14(4), 1099-1105 (2007). (Pubitemid 351252441)
35. Kakudo K, Tang W, Ito Y, Mori I, Nakamura Y, Miyauchi A. Papillary carcinoma of the thyroid in Japan: subclassification of common type and identification of low risk group. J. Clin. Pathol. 57(10), 1041-1046 (2004). (Pubitemid 39331353)
36. Baloch ZW, LiVolsi VA. Our approach to follicular-patterned lesions of the thyroid. J. Clin. Pathol. 60(3), 244-250 (2007).
37. Ivanova R, Soares P, Castro P, Sobrinho-Simões M. Diffuse (or multinodular) follicular variant of papillary thyroid carcinoma: a clinicopathologic and immunohistochemical analysis of ten cases of an aggressive form of differentiated thyroid carcinoma. Virchows Arch. 440(4), 418-424 (2002). (Pubitemid 34328075)
38. Liu J, Singh B, Tallini G et al. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer 107(6), 1255-1264 (2006). (Pubitemid 44452774)
39. Baloch ZW, LiVolsi VA. Encapsulated follicular variant of papillary thyroid carcinoma with bone metastases. Mod. Pathol. 13(8), 861-865 (2000).
40. Jarzab B, Handkiewicz Junak D, Wloch J et al. Multivariate analysis of prognostic factors for differentiated thyroid carcinoma in children. Eur. J. Nucl. Med. 27(7), 833-841 (2000). (Pubitemid 30456766)
41. La Quaglia MP, Black T, Holcomb GW 3rd et al. Differentiated thyroid cancer: clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases: a report from the Surgical Discipline Committee of the Children's Cancer Group. J. Pediatr. Surg. 35(6), 955-959 (2000). • One of the most cited papers dealing with differentiated thyroid carcinoma in children. (Pubitemid 30346195)
42. Mirallié E, Visset J, Sagan C, Hamy A, Le Bodic MF, Paineau J. Localization of cervical node metastasis of papillary thyroid carcinoma. World J. Surg. 23(9), 970-973 (1999). (Pubitemid 29398483)
43. Watkinson JC, Franklyn JA, Olliff JF. Detection and surgical treatment of cervical lymph nodes in differentiated thyroid cancer. Thyroid 16(2), 187-194 (2006).
44. Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin- stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J. Clin. Endocrinol. Metab. 90(9), 5047-5057 (2005).
45. Alfalah H, Cranshaw I, Jany T et al. Risk factors for lateral cervical lymph node involvement in follicular thyroid carcinoma. World J. Surg. 32(12), 2623-2626 (2008).
46. Witte J, Goretzki PE, Dieken J, Simon D, Röher HD. Importance of lymph node metastases in follicular thyroid cancer. World J. Surg. 26(8), 1017-1022 (2002). (Pubitemid 36920302)
47. Podnos YD, Smith D, Wagman LD, Ellenhorn JD. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am. Surg. 71(9), 731-734 (2005).
48. Leboulleux S, Rubino C, Baudin E et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J. Clin. Endocrinol. Metab. 90(10), 5723-5729 (2005). •• Deals with the impact of nonencapsulated tumors and neck lymph node metastases on recurrence and survival in a large series of patients operated on for papillary thyroid cancer (PTC) and with a mean follow-up of 8 years. (Pubitemid 41415482)
49. Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid - prognostic significance of lymph node metastasis and multifocality. Cancer 98(1), 31-40 (2003). (Pubitemid 36741122)
50. Hughes CJ, Shaha AR, Shah JP, Loree TR. Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis. Head Neck 18(2), 127-132 (1996).
51. Shaha AR. TNM classification of thyroid carcinoma. World J. Surg. 31(5), 879-887 (2007).
52. Miccoli P, Antonelli A, Spinelli C, Ferdeghini M, Fallahi P, Baschieri L. Completion total thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident. Arch. Surg. 133(1), 89-93 (1998). (Pubitemid 28053173)
53. Schlumberger M, Challeton C, De Vathaire F, Parmentier C. Treatment of distant metastases of differentiated thyroid carcinoma. J. Endocrinol. Invest. 18(2), 170-172 (1995).
54. Schlumberger M, Tubiana M, De Vathaire F et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 63(4), 960-967 (1986). (Pubitemid 16004302)
55. Sisson JC, Giordano TJ, Jamadar DA et al. 131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. Cancer 78(10), 2184-2192 (1996).
56. Schlumberger MJ. Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J. Endocrinol. Invest. 22(11 Suppl.), 3-7 (1999).
57. Sakorafas GH, Giotakis J, Stafyla V. Papillary thyroid microcarcinoma: a surgical perspective. Cancer Treat. Rev. 31(6), 423-438 (2005). (Pubitemid 41536166)
58. MacCorkle RA, Tan TH. Mitogen-activated protein kinases in cell-cycle control. Cell Biochem. Biophys. 43, 451-461 (2005).
59. Robinson MJ, Cobb MH Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 9, 180-186 (1997).
60. Torii S, Nakayama K, Yamamoto T, Nishida E. Regulatory mechanisms and function of ERK MAP kinases. J. Biochem. (Tokyo) 136, 557-561 (2004). (Pubitemid 40364176)
61. Kohno M, Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. Ann. Med. 38, 200-211 (2006). (Pubitemid 43675585)
62. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim. Biophys. Acta 1653, 25-40 (2003).
63. Rodriguez-Viciana P, Tetsu O, Oda K et al. Cancer targets in the Ras pathway. Cold Spring Harb. Symp. Quant. Biol. 70, 461-467 (2005).
64. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 4, 937-947 (2004). (Pubitemid 39626217)
65. Hoshino R, Chatani Y, Yamori T et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18, 813-822 (1999). (Pubitemid 29080340)
66. Knauf JA, Kuroda H, Basu S, Fagin JA RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 22, 4406-4412 (2003). (Pubitemid 36897971)
67. Melillo RM, Castellone MD, Guarino V et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J. Clin. Invest. 115, 1068-1081 (2005). (Pubitemid 40489412)
68. Mitsutake N, Miyagishi M, Mitsutake S et al. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinology 147, 1014-1019 (2006). (Pubitemid 43113021)
69. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002). (Pubitemid 34716871)
70. Dhomen N, Marais R New insight into BRAF mutations in cancer. Curr. Opin. Genet. Dev. 17, 31-39 (2007). (Pubitemid 46109299)
71. Garnett MJ, Marais R Guilty as charged: BRAF is a human oncogene. Cancer Cell 6, 313-319 (2004).
72. Xing M. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 12, 245-262 (2005).
73. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr. Rev. 28(7), 742-762 (2007). (Pubitemid 350294294)
74. Lupi C, Giannini R, Ugolini C et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 92(11), 4085-4090 (2007). •• Largest series described to date about BRAF mutation status in a consecutive series of PTC patients. (Pubitemid 350074715)
75. Porra V, Ferraro-Peyret C, Durand C et al. Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J. Clin. Endocrinol. Metab. 90, 3028-3035 (2005). (Pubitemid 40686360)
76. Mitsutake N, Knauf JA, Mitsutake S, Mesa C Jr, Zhang L, Fagin JA. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res. 65, 2465-2473 (2005). (Pubitemid 40490159)
77. Knauf JA, Ma X, Smith EP et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 65, 4238-4245 (2005). (Pubitemid 40775662)
78. Xing M, Westra WH, Tufano RP et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 90, 6373-6379 (2005). (Pubitemid 41759286)
79. Giordano TJ, Kuick R, Thomas DG et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24, 6646-6656 (2005). (Pubitemid 41486795)
80. Oler G, Cerutti JM. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer 115(5), 972-980 (2009).
81. Espadinha C, Santos JR, Sobrinho LG, Bugalho MJ. Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAFV600E mutation dependency. Clin. Endocrinol. (Oxf.) 70(4), 629-635 (2009).
82. Durante C, Puxeddu E, Ferretti E et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J. Clin. Endocrinol. Metab. 92(7), 2840-2843 (2007). (Pubitemid 47037399)
83. Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin. Cancer Res. 13(4), 1341-1349 (2007). (Pubitemid 46424076)
84. De Lellis RA. Pathology and genetics of thyroid carcinoma. J. Surg. Oncol. 15, 94(8), 662-669 (2006).
85. Patel KN, Singh B. Molecular advances in thyroid cancer. In: Thyroid and Parathyroid Diseases, Medical and Surgical Management. Terris D, Gourin CG (Eds), Thieme, NY, USA (2009).
86. Roccato E, Bressan P, Sabatella G et al. Proximity of TPR and NTRK1 rearranging loci in human thyrocytes. Cancer Res. 65(7), 2572-2576 (2005). (Pubitemid 40490053)
87. Santoro M, Sabino N, Ishizaka Y et al. Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours. Br. J. Cancer 68(3), 460-464 (1993). (Pubitemid 23258446)
88. Bongarzone I, Fugazzola L, Vigneri P et al. Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 81(5), 2006-2009 (1996).
89. Fugazzola L, Pilotti S, Pinchera A et al. Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res. 55(23), 5617-5620 (1995).
90. Bounacer A, Wicker R, Caillou B et al. High prevalence of activating RET proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 15(11), 1263-1273 (1997). (Pubitemid 27429741)
91. Tallini G, Asa SL. RET oncogene activation in papillary thyroid carcinoma. Adv. Anath. Pathol. 8, 345-354 (2001).
92. Tallini G, Santoro M, Helie M et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin. Cancer Res. 4(2), 287-294 (1998). (Pubitemid 28122740)
93. Lanzi C, Cassinelli G, Pensa T et al. Inhibition of transforming activity of the RET/PTC1 oncoprotein by a 2-indolinone derivative. Int. J. Cancer 85(3), 384-390 (2000). (Pubitemid 30030413)
94. Barbacid M. RAS genes. Annu. Rev. Biochem. 56, 779-827 (1987).
95. Finney RE, Bishop JM. Predisposition to neoplastic transformation caused by gene replacement of H-ras1. Science 260(5113), 1524-1527 (1993).
96. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J. Clin. Endocrinol. Metab. 88(6), 2745-2752 (2003). (Pubitemid 36724451)
97. Adeniran AJ, Zhu Z, Gandhi M et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am. J. Surg. Pathol. 30(2), 216-222 (2006). (Pubitemid 43740191)
98. Ngan ES, Lang BH, Liu T et al. A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma. J. Natl Cancer Inst. 101(3), 162-175 (2009). • Description of a potentially useful marker to lower the incidence of PTC incidentally discovered after thyroidectomy for supposedly benign disease.
99. Fabbro D, Di Loreto C, Beltrami CA, Belfiore A, Di Lauro R, Damante G. Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res. 54(17), 4744-4749 (1994). (Pubitemid 24276506)
100. Tallini G. Molecular pathobiology of thyroid neoplasms. Endocr. Pathol. 13(4), 271-288 (2002).
101. Kroll TG, Sarraf P, Pecciarini L et al. PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma (corrected). Science 289(5483), 1357-1360 (2000). Erratum in: Science 289 (5484), 1474 (2000).
102. Ying H, Suzuki H, Zhao L, Willingham MC, Meltzer P, Cheng SY. Mutant thyroid hormone receptor β represses the expression and transcriptional activity of peroxisome proliferator-activated receptor γ during thyroid carcinogenesis. Cancer Res. 63(17), 5274-5280 (2003). (Pubitemid 37139841)
103. Nikiforov YE. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr. Pathol. 15(4), 319-327 (2004).
104. Marques AR, Espadinha C, Catarino AL et al. Expression of PAX8-PPARγ1 rearrangements in both follicular thyroid carcinomas and adenomas. J. Clin. Endocrinol. Metab. 87(8), 3947-3952 (2002). (Pubitemid 34879553)
105. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE. PAX8-PPARγ rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am. J. Surg. Pathol. 26(8), 1016-1023 (2002).
106. Grommes C, Landreth, GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. Lancet Oncol. 5, 419-429 (2004). (Pubitemid 38878045)
107. Antonelli A, Rotondi M, Ferrari SM et al. Interferon-γ-inducible α-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-γ agonists. J. Clin. Endocrinol. Metab. 91, 614-620 (2006). (Pubitemid 43236933)
108. Frohlich E, Machicao F, Wahl R. Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocr. Relat. Cancer 12, 291-303 (2005). (Pubitemid 40896448)
109. Kebebew E, Peng M, Reiff E et al. A Phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 140, 960-966 (2006). (Pubitemid 44937397)
110. Tepmongkol S, Keelawat S, Honsawek S, Ruangvejvorachai P. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-γ. Thyroid 18, 697-704 (2008). (Pubitemid 352009939)
111. Sahin M, Allard BL, Yates M et al. PPARγ staining as a surrogate for PAX8/PPARγ fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. J. Clin. Endocrinol. Metab. 90, 463-468 (2005). (Pubitemid 40116695)
112. Antonelli A, Ferrari SM, Fallahi P et al. Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clin. Endocrinol. (Oxf.) 70(6), 946-953 (2008).
113. Eszlinger M, Krohn K, Hauptmann S, Dralle H, Giordano TJ, Paschke R. Perspectives for improved and more accurate classification of thyroid epithelial tumors. J. Clin. Endocrinol. Metab. 93(9), 3286-3294 (2008).
114. Detours V, Versteyhe S, Dumont JE, Maenhaut C. Gene expression profiles of post-Chernobyl thyroid cancers. Curr. Opin. Endocrinol. Diabetes Obes. 15(5), 440-445 (2008).
115. Puxeddu E, Moretti S. Clinical prognosis in BRAF-mutated PTC. Arq. Bras. Endocrinol. Metabol. 51(5), 736-747 (2007).
116. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353(2), 172-187 (2005).
117. Fagin JA. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J. Endocrinol. 183(2), 249-256 (2004).
118. Ouyang B, Knauf JA, Smith EP et al. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin. Cancer Res. 12(6), 1785-1793 (2006).
119. de la Torre NG, Buley I, Wass JA, Turner HE. Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. Endocr. Relat. Cancer 13(3), 931-944 (2006). (Pubitemid 44763268)
120. Schoenberger J, Grimm D, Kossmehl P, Infanger M, Kurth E, Eilles C. Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study. Endocrinology 145(3), 1031-1038 (2004). (Pubitemid 38280976)
121. Younes MN, Yazici YD, Kim S, Jasser SA, El-Naggar AK, Myers JN. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer. Clin. Cancer Res. 12(11 Pt 1), 3425-3434 (2006). (Pubitemid 43910888)
122. Knauf JA, Ma X, Smith EP et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 65(10), 4238-4245 (2005). (Pubitemid 40775662)
123. Santoro M, Carlomagno F. Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nat. Clin. Pract. Endocrinol. Metab. 2(1), 42-52 (2006).
124. Polverino A, Coxon A, Starnes C et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 66(17), 8715-8721 (2006). (Pubitemid 44449188)
125. Carlomagno F, Anaganti S, Guida T et al. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl Cancer Inst. 98(5), 326-334 (2006). (Pubitemid 43338212)
126. Kim DW, Jo YS, Jung HS et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J. Clin. Endocrinol. Metab. 91(10), 4070-4076 (2006).
127. Vidal M, Wells S, Ryan A, Cagan R. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res. 65(9), 3538-3541 (2005). (Pubitemid 40616327)
128. Boughton D, Rosen L, Van Vugt A et al. Safety and antitumor activity of AMG 706 in patients (pts) with thyroid cancer (TC): a subset analysis from a Phase 1 dose-finding study. Program and abstracts at the 42nd Annual ASCO Meeting. Atlanta, GA, USA, 2-6 June 2006 (Abstract 3030).
129. Kim S, Rosen LS, Cohen EE et al. A Phase II study of axinitib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer. Program and abstracts at the 42nd Annual ASCO Meeting. Atlanta, GA, USA, 2-6 June 2006 (Abstract 5529).
130. Kloos R, Ringel M, Knopp M et al. Significant clinical and biologic activity of RAF/VEGF-R kinase inhibitor BAY 43-9006 in patients with metastatic papillary thyroid carcinoma (PTC): updated results of a Phase II study. Program and abstracts at the 42nd Annual ASCO Meeting. Atlanta, GA, USA, 2-6 June 2006 (Abstract 5534).
131. Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM, Haugen BR. Retinoid X receptor-γ and peroxisome proliferator-activated receptor-γ expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Mol. Cancer Ther. 3(8), 1011-1020 (2004). (Pubitemid 39199596)
132. Philips JC, Petite C, Willi JP, Buchegger F, Meier CA. Effect of peroxisome proliferator-activated receptor γ agonist, rosiglitazone, on dedifferentiated thyroid cancers. Nucl. Med. Commun. 25(12), 1183-1186 (2004). (Pubitemid 39614279)
133. Park JW, Zarnegar R, Kanauchi H et al. Troglitazone, the peroxisome proliferator-activated receptor-γ agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 15(3), 222-231 (2005). (Pubitemid 40418689)
134. Hayashi N, Nakamori S, Hiraoka N et al. Antitumor effects of peroxisome proliferator activate receptor γ ligands on anaplastic thyroid carcinoma. Int. J. Oncol. 24(1), 89-95 (2004).
135. Antonelli A, Ferrari SM, Fallahi P et al. Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. Eur. J. Endocrinol. 159(3), 283-291 (2008). (Pubitemid 351847276)
136. Antonelli A, Ferrari SM, Fallahi P et al. Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests. Clin. Endocrinol. (Oxf.) 69(1), 148-152 (2008). (Pubitemid 351847276)
137. Antonelli A, Fallahi P, Ferrari SM et al. Dedifferentiated thyroid cancer: a therapeutic challenge. Biomed. Pharmacother. 62(8), 559-563 (2008).
138. Miccoli P, Berti P, Materazzi G, Minuto M, Barellini L. Minimally invasive video-assisted thyroidectomy: five years of experience. J. Am. Coll. Surg. 199(2), 243-248 (2004). (Pubitemid 38622413)
139. Terris DJ, Opraseuth J. Minimally invasive reoperative thyroid surgery. Otolaryngol. Clin. North Am. 41(6), 1199-1205 (2008).
140. Wang M, Zhang T, Mao Z et al. Effect of endoscopic thyroidectomy via anterior chest wall approach on treatment of benign thyroid tumors. J. Laparoendosc. Adv. Surg. Tech. 19(2), 149-152 (2009).
141. Benhidjeb T, Wilhelm T, Harlaar J et al. Natural orifice surgery on thyroid gland: totally transoral video-assisted thyroidectomy (TOVAT): report of first experimental results of a new surgical method. Surg. Endosc. 23(5), 1119-1120 (2009).
142. Perigli G, Cortesini C, Quirici E, Boni D, Cianchi F. Clinical benefits of minimally invasive techniques in thyroid surgery. World J. Surg. 32(1), 45-50 (2008). (Pubitemid 50001736)
143. Miyano G, Lobe TE, Wright SK. Bilateral transaxillary endoscopic total thyroidectomy. J. Pediatr. Surg. 43(2), 299-303 (2008). (Pubitemid 351226215)
144. Miccoli P, Pinchera A, Materazzi G et al. Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy. J. Clin. Endocrinol. Metab. 94(5), 1618-1622 (2009).
145. Miccoli P, Elisei R, Donatini G, Materazzi G, Berti P. Video-assisted central compartment lymphadenectomy in a patient with a positive RET oncogene: initial experience. Surg. Endosc. 21(1), 120-123 (2007). (Pubitemid 44951362)
146. Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PP. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J. Clin. Endocrinol. Metab. 82(11), 3553-3562 (1997).
147. Haigh PI, Urbach DR, Rotstein LE. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Ann. Surg. Oncol. 12(1), 81-89 (2005).
148. Miccoli P, Minuto MN, Ugolini C et al. Intrathyroidal differentiated thyroid carcinoma: tumor size-based surgical concepts. World J. Surg. 31(5), 888-894 (2007). (Pubitemid 46716776)
149. Wanebo H, Coburn M, Teates D, Cole B. Total thyroidectomy does not enhance disease control or survival even in high-risk patients with differentiated thyroid cancer. Ann. Surg. 227(6), 912-921 (1998). (Pubitemid 29119539)
150. Wada N, Duh QY, Sugino K et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann. Surg. 237(3), 399-407 (2003). (Pubitemid 38176456)
151. Giusti L, Iacconi P, Ciregia F et al. Fine-needle aspiration of thyroid nodules: proteomic analysis to identify cancer biomarkers. J. Proteome Res. 7(9), 4079-4088 (2008).
152. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102(6), 1088-1095 (1987). • First description of one of the most used systems for risk stratification for PTC.
153. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104(6), 947-953 (1988). • First description of another commonly used classification system for for PTC. (Pubitemid 19011971)
154. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114(6), 1050-1057 (1993).
155. Greene FL, Compton CC, Fritz AG, Shah JP, Winchester DP. AJCC Cancer Staging Atlas (6th Edition). Springer Educational, NY, USA (2006).
156. Byar DP, Green SB, Dor P et al. A prognostic index for thyroid carcinoma: a study of the E.O.R.T.C: Thyroid Cancer Cooperative Group. Eur. J. Cancer 15(8), 1033-1041 (1979). (Pubitemid 9254743)
157. Mazzaferri EL. Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr. Pract. 6(6), 469-476 (2000).
158. Degroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 71, 414-424 (1990). (Pubitemid 20261828)
159. Nikiforova MN, Kimura ET, Gandhi M et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 88(11), 5399-5404 (2003). (Pubitemid 37452745)
160. Kim TY, Kim WB, Song JY et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin. Endocrinol. (Oxf.) 63(5), 588-593 (2005).
161. Liu RT, Chen YJ, Chou FF et al. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin. Endocrinol. (Oxf.) 63(4), 461-466 (2005).
162. Abrosimov A, Saenko V, Rogounovitch T et al. Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status. Int. J. Cancer 120(1), 196-200 (2007). (Pubitemid 44901936)
163. Kim J, Giuliano AE, Turner RR et al. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann. Surg. 244(5), 799-804 (2006). (Pubitemid 44629955)
164. Park SY, Park YJ, Lee YJ et al. Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. Cancer 107(8), 1831-1838 (2006).
165. +/I-targeting to the membrane. Endocr. Relat. Cancer 13(1), 257-269 (2006).
166. Kebebew E, Weng J, Bauer J et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann. Surg. 246(3), 466-470 (2007). (Pubitemid 47312140)
167. Elisei R, Ugolini C, Viola D et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J. Clin. Endocrinol. Metab. 93(10), 3943-3949 (2008).
168. Frasca F, Nucera C, Pellegriti G et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr. Relat. Cancer 15(1), 191-205 (2008).
169. Ito Y, Yoshida H, Maruo R et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr. J. 56(1), 89-97 (2009).
170. Xing M. Comments on the Ito et al. article. The lack of clinicopathological correlation of BRAF mutation in papillary thyroid cancer needs to be interpreted with caution. Endocr. J. 56(2), 305-306 (2009).
171. Ries LAG, Eisner MP, Kosary CL et al. SEER cancer statistics review, 1975-2001, National Cancer Institute, Bethesda, MD, USA http://seer.cancer.gov/ csr/1975.2001.
172. Ries LAG, Melbert D, Krapcho M et al. SEER cancer statistics review, 1975-2004. National Cancer Institute, Bethesda, MD, USA http://seer.cancer.gov/ csr/1975-2004/